Skip to main content
. 2020 Nov 30;9(2):709–722.e2. doi: 10.1016/j.jaip.2020.11.038

Figure 4.

Figure 4

(A) Comparison of in-hospital omalizumab injection appointments (median [IQR]) for chronic spontaneous urticaria for week commencing at 3 time points. (B) Comparison of patients receiving home omalizumab injection (median [IQR]) for chronic spontaneous urticaria for week commencing at 3 time points. (C) Comparison of numbers of new patient appointments (median [IQR]) for sublingual immunotherapy initiation for week commencing at 3 time points. (D) Comparison of patients receiving maintenance for sublingual immunotherapy (median [IQR]) for week commencing at 3 time points. IQR, Interquartile range; NS, not significant.